Products

  • Biosugrel

    Biosugrel®

    Prasugrel: Reduces rate of thrombotic cardiovascular events (eg, stent thrombosis) in patients with unstable angina

  • Biolozax h

    Biolozax-H®

    Losartan / Hydrochlorothiazide: Biolozax-H is indicated for the treatment of hypertension.Biolozax-H is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

  • Fenobiox  new

    Fenobiox®

    Fenofibrate: djunct to dietary therapy for the treatment of adults with elevations of serum triglyceride levels (types IV and V hyper lipidemia); adjunct to dietary therapy for the reduction of low density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb)

  • Domprex

    Domprex®

    Dompridone: Nausea and vomiting, dyspepsia, gastro-oesophageal reflux.

  • Biomigril

    Biomigril®

    Rizatriptan: Biomigril is indicated for the acute treatment of migraine attacks with or without aura in adults.

  • Zolmigran

    Zolmigran®

    Zolmitriptan: Zolmigran is indicated for the acute treatment of migraine with or without aura in adult

  • Buprobiox 100 & 75

    Buprobiox®

    Bupropion: Treatment of major depressive disorder

  • Bioquetine Eng

    Bioquetine®

    Quetiapine: Treatment of schizophrenia; treatment of acute manic episodes associated with bipolar disorder (as monotherapy or in combination with Lithium or Divalproex); maintenance treatment of bipolar disorder (in combination with Lithium or Divalproex); treatment of depressive episodes associated with bipolar disorder

  • Atobiox

    Atobiox®

    Atomoxetin: Atobiox is indicated for treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children (over 6 years old), teenagers and adults.

  • Biovirapine

    Biovirapine®

    Nevirapine: Biovirapine is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1-infection.

Copyright © 2024 Bakhtar Bioshimi Co, All rights reserved.